Citations

Clear

439 citation(s) found for "Stone, M".

Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main and Multivessel Coronary Artery Disease
Stone, Gregg W. , Bhatt, Deepak L. , Gersh, Bernard J. , Bhatt, Deepak L

Mayo Clinic

Circulation | February 27, 2017 | Volume: 135 | Issue: 9 | Pages: 819-821

10.1161/circulationaha.116.025263 | PMID 28242636 Get It

Superficialization of Deep Arteriovenous Access Procedures in Obese Patients Using Suction-Assisted Lipectomy: A Novel Approach
Krochmal, Daniel J., Rebecca, Alanna M. , Kalkbrenner, Kristen A., Casey, William J., Fowl, Richard J., Stone, William M., Chapital, Alyssa B. , Smith, Anthony A.

Mayo Clinic

Canadian Journal of Plastic Surgery | February 23, 2017 | Volume: 18 | Issue: 1 | Pages: 25-27

10.1177/229255031001800112 | PMID 21358871 Get It

Successful dialysis access necessitates superficial arteriovenous fistula (AVF) placement to facilitate identification of anatomical landmarks for safe cannulation. Suction-assisted lipectomy (SAL) may be an alternative to traditional surgical AVF revision procedures for placing fistulas more superficially. Three patients with an average body mass index of 45.2 kg/m 2 , with inaccessible AVFs due to obesity, underwent ultrasound-guided SAL of their upper extremities. Successful cannulation was achieved within two weeks. A clinically insignificant hematoma and arm swelling occurred in one patient. SAL provides a safe and effective alternative for salvaging deep AVFs for dialysis access in the upper extremities of obese patients.
Risk of Hypertension among First-Time Symptomatic Kidney Stone Formers
Kittanamongkolchai, Wonngarm , Mara, Kristin C. , Mehta, Ramila A. , Vaughan, Lisa E. , Đenić, Aleksandar , Knoedler, John, Knoedler, John J., Enders, Felicity , Lieske, John C. , Rule, Andrew D. , Denic, Aleksandar , Mara, Kristin C

Mayo Clinic

Clinical Journal of the American Society of Nephrology | February 1, 2017 | Volume: 12 | Issue: 3 | Pages: 476-482

10.2215/cjn.06600616 | PMID 28148559 Get It

Background and objectives Prior work has suggested a higher risk of hypertension in kidney stone formers but lacked disease validation and adjustment for potential confounders. Certain types of stone formers may also be at higher risk of hypertension. Design, setting, participants, & measurements In our study, incident symptomatic stone formers in Olmsted County from 2000 to 2011 were manually validated by chart review and age and sex matched to Olmsted County controls. We followed up patients through November 20, 2015. Hypertension was also validated by manual chart review, and the risk of hypertension in stone formers compared with controls was assessed both univariately and after adjusting for comorbidities. The risk of hypertension among different subtypes of stone formers was also evaluated. Results Among 3023 coded stone formers from 2000 to 2011, a total of 1515 were validated and matched to 1515 controls (mean age was 45 years old, and 56% were men). After excluding those with baseline hypertension (20% of stone formers and 18% of controls), 154 stone formers and 110 controls developed hypertension. Median follow-up time was 7.8 years in stone formers and 9.6 years in controls. Stone formers were found to have a higher risk of hypertension compared with controls (hazard ratio, 1.50; 95% confidence interval, 1.18 to 1.92), even after adjusting for age, sex, body mass index, serum creatinine, CKD, diabetes, gout, coronary artery disease, dyslipidemia, tobacco use, and alcohol abuse (hazard ratio, 1.58; 95% confidence interval, 1.12 to 2.21). Results were similar after excluding patients who were ever on a thiazide diuretic (hazard ratio, 1.65; 95% confidence interval, 1.16 to 2.38). Stone composition, radiographic stone burden, number of subsequent stone events, and stone removal surgeries were not associated with hypertension ( P >0.05 for all). Conclusions The risk of hypertension was higher after the first symptomatic kidney stone event. However, kidney stone severity, type, and treatment did not associate with hypertension.
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001
Uy, Geoffrey L. , Mandrekar, Sumithra J. , Laumann, Kristina, Marcucci, Guido , Zhao, Weiqiang , Baer, Maria R. , Powell, Bayard L., Westervelt, Peter, DeAngelo, Daniel J. , Sanford, Ben L. , Blum, William , Bloomfield, Clara D. , Stone, Richard M. , Levis, Mark J. , Klepin, Heidi D. , Stock, Wendy , Larson, Richard A. , Uy, Geoffrey , Deangelo, D. J.

Mayo Clinic

Blood Advances | January 25, 2017 | Volume: 1 | Issue: 5 | Pages: 331-340

10.1182/bloodadvances.2016003053 | PMID 29034366 Get It

Key Points The addition of sorafenib to chemotherapy for older adults with FLT3-ITD mutated AML is safe and may improve overall survival.
Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era
Mantha, Simon , Goldman, Debra A., Lee, Ju-Whei, Zannino, Diana , Collins, Marnie, Douer, Dan , Iland, Harry , Litzow, Mark R. , Stein, Eytan M. , Appelbaum, Frederick R. , Stone, Richard M. , Powell, Bayard L., Geyer, Susan, Laumann, Kristina, Rowe, Jacob M. , Coutré, Steven , Park, Jae H. , Wiernik, Peter H. , Tallman, Martin S. , Devlin, Sean M. , Lee, Ju‐Whei , Larson, Richard A. , Erba, Harry Paul , Othus, Megan

Mayo Clinic

Blood | January 13, 2017 | Volume: 129 | Issue: 13 | Pages: 1763-1767

10.1182/blood-2016-10-747170 | PMID 28082441 Get It

Key Points High WBC is an independent predictor of early HD in APL.
Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis
Clain, Jeremy M., Hummel, Amber M., Stone, John H. , Hoffman, Gary S., Kallenberg, C. G. M., Langford, Carol A. , McCune, W. Joseph, Clair, E. William St. , Ytterberg, Steven R. , Fervenza, Fernando C. , Merkel, Peter A. , Monach, Paul A. , Seo, Philip , Spiera, Robert , Specks, Ulrich

Mayo Clinic

Clinical and Experimental Immunology | January 11, 2017 | Volume: 188 | Issue: 1 | Pages: 174-181

10.1111/cei.12925 | PMID 28076879 Get It

Summary Anti-neutrophil cytoplasmic antibodies (ANCA) appear to play an important role in the pathogenesis of ANCA-associated vasculitis (AAV). However, ANCA alone are not sufficient to generate disease, and some evidence suggests that infectious triggers may serve as inciting events for AAV disease activity. Antibodies of the immunoglobulin (Ig)M isotype often serve as markers of recent infection, and IgM ANCA have been identified previously in patients with AAV, although the frequency and clinical relevance of IgM ANCA is not well established. We sought to characterize IgM ANCA more clearly by creating a novel enzyme-linked immunosorbent assay (ELISA) for IgM antibodies to proteinase 3 [IgM proteinase 3 (PR3)–ANCA], which we applied to two large, clinically well-characterized trial cohorts of patients with granulomatosis with polyangiitis and microscopic polyangiitis. In the first cohort, IgM PR3–ANCA occurred with a frequency of 15·0%, and were associated with a higher degree of disease severity and a trend towards a higher rate of alveolar haemorrhage (29·6 versus 15·7%, P = 0·10). Analysis of follow-up samples in this cohort showed that the presence of IgM PR3–ANCA was transient, but could recur. In the second cohort, IgM PR3–ANCA occurred with a frequency of 41·1%, and were also associated with a higher degree of disease severity. A higher rate of alveolar haemorrhage was observed among those with IgM PR3–ANCA (45·3 versus 15·8%; P < 0·001). The association of transient IgM PR3–ANCA with an acute respiratory manifestation of AAV suggests a possible link between an infectious trigger and AAV disease activity.
Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis
Ji, Xuemei , Ciavatta, Dominic J. , Pinder, Benjamin D. , Zhao, Ai, Zhang, Jinyi , Tadesse, Yohannes, Qian, David C. , Nair, Rajan P. , Tsoi, Lam C. , Carette, Simon , Cuthbertson, David , Davis, John C. , Dellaripa, Paul F., Forbess, Lindsy, Gewurz‐Singer, Ora, Hoffman, Gary S., Koening, Curry L. , Langford, Carol A. , Mahr, Alfred , McAlear, Carol A. , Moreland, Larry W. , Seo, Philip , Sreih, Antoine G. , Clair, E. William St. , Stone, John H., Ytterberg, Steven R. , Elder, James T. , Qu, Jia , Ochi, Toshiki , Hirano, Naoto , Edberg, Jeffrey C., Falk, Ronald J. , Siminovitch, Katherine A. , Merkel, Peter A. , Xie, Gang , Monach, Paul A. , Byun, Jinyoung , Weirauch, Matthew T. , Pagnoux, Christian , Chung, Sharon A. , Dellaripa, Paul F. , Khalidi, Nader , Specks, Ulrich , Spiera, Robert , Amos, Christopher I. , Mahr, Alfred , Moreland, Larry W , Tsoi, Lam C

Mayo Clinic

Arthritis & Rheumatology | December 28, 2016 | Volume: 69 | Issue: 5 | Pages: 1054-1066

10.1002/art.40034 | PMID 28029757 Get It

Objective To identify risk alleles relevant to the causal and biologic mechanisms of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). Methods A genome‐wide association study and subsequent replication study were conducted in a total cohort of 1,986 cases of AAV (patients with granulomatosis with polyangiitis [Wegener's] [GPA] or microscopic polyangiitis [MPA]) and 4,723 healthy controls. Meta‐analysis of these data sets and functional annotation of identified risk loci were performed, and candidate disease variants with unknown functional effects were investigated for their impact on gene expression and/or protein function. Results Among the genome‐wide significant associations identified, the largest effect on risk of AAV came from the single‐nucleotide polymorphism variants rs141530233 and rs1042169 at the HLA–DPB1 locus (odds ratio [OR] 2.99 and OR 2.82, respectively) which, together with a third variant, rs386699872, constitute a triallelic risk haplotype associated with reduced expression of the HLA–DPB1 gene and HLA–DP protein in B cells and monocytes and with increased frequency of complementary proteinase 3 (PR3)–reactive T cells relative to that in carriers of the protective haplotype. Significant associations were also observed at the SERPINA1 and PTPN22 loci, the peak signals arising from functionally relevant missense variants, and at PRTN3 , in which the top‐scoring variant correlated with increased PRTN3 expression in neutrophils. Effects of individual loci on AAV risk differed between patients with GPA and those with MPA or between patients with PR3‐ANCAs and those with myeloperoxidase‐ANCAs, but the collective population attributable fraction for these variants was substantive, at 77%. Conclusion This study reveals the association of susceptibility to GPA and MPA with functional gene variants that explain much of the genetic etiology of AAV, could influence and possibly be predictors of the clinical presentation, and appear to alter immune cell proteins and responses likely to be key factors in the pathogenesis of AAV.
Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States
Pine, Alexander B. , Sekeres, Mikkael A. , Zelterman, Daniel , Komrokji, Rami S. , Litzow, Mark R. , Luger, Selina M. , Stone, Richard M. , Garcia‐Manero, Guillermo , Lee, Alfred Ian , Barbarotta, Lisa, Kasberg, Stephanie, Gore, Steven D. , Zeidan, Amer M. , Lee, Eun‐Ju , Steensma, David P. , Prébet, Thomas , Dezern, Amy Elizabeth , Erba, Harry Paul , Podoltsev, Nikolai , Hendrickson, Jeanne E. , Komrokji, Rami S , Sekeres, Mikkael A , Zeidan, Amer M

Mayo Clinic

Transfusion | November 23, 2016 | Volume: 57 | Issue: 2 | Pages: 289-295

10.1111/trf.13934 | PMID 27878822 Get It

BACKGROUNDTransfusion of blood products is a key component of the supportive management in patients with acute leukemia (AL). However high‐quality trial evidence and clinical outcome data to support specific transfusion goals for blood products for patients with AL remain limited leading to diverse transfusion practices. The primary objective of this study was to determine the spectrum of transfusion patterns in a variety of care settings among providers who treat AL patients.STUDY DESIGN AND METHODSA 31‐question survey queried providers caring for AL patients about the existence of institutional guidelines for transfusion of blood products, transfusion triggers for hemoglobin (Hb), platelets (PLTs), and fibrinogen in various settings including inpatient and outpatient and before procedures.RESULTSWe analyzed 130 responses and identified divergent transfusion Hb goals in hospitalized and ambulatory patients, fibrinogen goals for cryoprecipitate transfusions, and variation in practice for use of certain PLTs and red blood cell products. The least variable transfusion patterns were reported for PLT goals in thrombocytopenia and in the setting of invasive procedures such as bone marrow biopsy and lumbar punctures.CONCLUSIONSThis survey confirmed wide variations in blood product transfusion practices across several clinical scenarios in patients with AL. The findings emphasized the need for large prospective randomized trials to develop standardized evidence‐based guidelines for blood product transfusions in patients with AL with the goal of limiting unnecessary transfusions without compromising outcomes.
Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality
Eisfeld, Ann‐Kathrin , Kohlschmidt, Jessica, Mrózek, Krzysztof , Volinia, Stefano , Blachly, James S. , Oakes, Christopher C. , Kroll, Karl, Carroll, Andrew J. , Stone, Richard M. , Byrd, John C. , Chapelle, Albert de la , Bloomfield, Clara D. , Byrd, John C. , Nicolet, Deedra , Orwick, Shelley J. , Blachly, James , Byrd, John C

Mayo Clinic

Cancer Research | October 26, 2016 | Volume: 77 | Issue: 1 | Pages: 207-218

10.1158/0008-5472.can-16-1386 | PMID 27784745 Get It

Abstract Monosomy of chromosome 7 is the most frequent autosomal monosomy in acute myeloid leukemia (AML), where it associates with poor clinical outcomes. However, molecular features associated with this sole monosomy subtype (-7 AML), which may give insights into the basis for its poor prognosis, have not been characterized. In this study, we analyzed 36 cases of -7 AML for mutations in 81 leukemia/cancer-associated genes using a customized targeted next-generation sequencing panel (Miseq). Global gene and miRNA expression profiles were also determined using paired RNA and small RNA sequencing data. Notably, gene mutations were detected in all the major AML-associated functional groups, which include activated signaling, chromatin remodeling, cohesin complex, methylation, NPM1, spliceosome, transcription factors, and tumor suppressors. Gene mutations in the chromatin remodeling groups were relatively more frequent in patients <60 years of age, who also had less mutations in the methylation and spliceosome groups compared with patients ≥60 years of age. Novel recurrent mutational events in AML were identified in the SMARCA2 gene. In patients ≥60 years of age, the presence of spliceosome mutations associated with a lower complete remission rate (P = 0.03). RNA sequencing revealed distinct gene and miRNA expression patterns between the sole -7 and non -7 AML cases, with reduced expression, as expected, of many genes and miRNAs mapped to chromosome 7, and overexpression of ID1, MECOM, and PTPRM, among others. Overall, our findings illuminate a number of molecular features of the underlying aggressive pathobiology in -7 AML patients. Cancer Res; 77(1); 207–18. ©2016 AACR.
Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Wallace, Zachary S. , Miloslavsky, Eli M. , Cascino, Matthew D., Unizony, Sebastian , Lu, Na , Hoffman, Gary S., Kallenberg, Cees G. M., Langford, Carol A. , Clair, E. William St. , Brunetta, Paul , Stone, John H. , Merkel, Peter A. , Monach, Paul A. , Seo, Philip , Spiera, Robert , Specks, Ulrich , Choi, Hyon K.

Mayo Clinic

Arthritis Care & Research | October 7, 2016 | Volume: 69 | Issue: 7 | Pages: 1004-1010

10.1002/acr.23099 | PMID 27696762 Get It

ObjectiveWe investigated the relationships between glucocorticoid use, disease activity, and changes in body mass index (BMI) in patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV).MethodsWe analyzed AAV patients enrolled in the Rituximab in AAV trial. Glucocorticoid use, BMI, and disease activity were measured regularly during the trial period. We performed mixed‐effects regressions to examine the associations of time‐dependent cumulative average glucocorticoid use and disease activity with changes in BMI over time, while adjusting for potential confounders.ResultsThe mean ± SD baseline BMI of the 197 patients enrolled was 28.8 ± 6.3 kg/m2. Patients with newly diagnosed AAV tended to have a lower mean ± SD BMI than those with relapsing disease (28.0 ± 5.7 kg/m2 versus 29.6 ± 6.8 kg/m2) and higher disease activity (mean ± SD Birmingham Vasculitis Activity Score for Wegener's Granulomatosis 8.7 ± 3.3 versus 7.4 ± 2.7). The most significant change in BMI occurred during the first 6 months of the trial (mean ± SD increase of 1.1 ± 2.2 kg/m2; P < 0.0001). Disease activity improvement, glucocorticoid exposure, and randomization to rituximab were each independently associated with an increase in BMI (P < 0.001 for all analyses).ConclusionOur findings suggest that changes in BMI, as well as glucocorticoid exposure, are independently associated with improvements in disease activity in AAV. Rituximab may also have effects on BMI independent of its impact on disease activity.